Abstract

Disulfide bonds contribute to protein stability, activity, and folding in a variety of proteins, including many involved in bacterial virulence such as toxins, adhesins, flagella, and pili, among others. Therefore, inhibitors of disulfide bond formation enzymes could have profound effects on pathogen virulence. In the Escherichia coli disulfide bond formation pathway, the periplasmic protein DsbA introduces disulfide bonds into substrates, and then the cytoplasmic membrane protein DsbB reoxidizes DsbA's cysteines regenerating its activity. Thus, DsbB generates a protein disulfide bond de novo by transferring electrons to the quinone pool. We previously identified an effective pyridazinone-related inhibitor of DsbB enzymes from several Gram-negative bacteria. To map the protein residues that are important for the interaction with this inhibitor, we randomly mutagenized by error-prone PCR the E. coli dsbB gene and selected dsbB mutants that confer resistance to this drug using two approaches. We characterized in vivo and in vitro some of these mutants that map to two areas in the structure of DsbB, one located between the two first transmembrane segments where the quinone ring binds and the other located in the second periplasmic loop of DsbB, which interacts with DsbA. In addition, we show that a mutant version of a protein involved in lipopolysaccharide assembly, lptD4213, is synthetically lethal with the deletion of dsbB as well as with DsbB inhibitors. This finding suggests that drugs decreasing LptD assembly may be synthetically lethal with inhibitors of the Dsb pathway, potentiating the antibiotic effects.

Highlights

  • The more DsbB inhibition of a drug the more ␤-galactosidase activity will be observed in cells, so one can calculate the concentration that gives 50% of inhibition (RIC50) of the total activity observed in a ⌬dsbB strain and use that concentration to get the fold-increase by dividing the relative inhibitory concentration 50 (RIC50) of compound 12 (0.16 ␮M, 95% confidence interval 0.13– 0.20 ␮M) between the RIC50 of the tested drug

  • We cannot rule out the possibility that the increase in DsbB levels may contribute to the resistance of DsbBK39E, the purified mutant displayed significantly different kinetics than the wild type enzyme, suggesting that the resistance conferred by the mutation is at least partially due to its effects on enzyme activity

  • Two mutants DsbBK39E and DsbBF106L show an increase in kcat implying that the reacϩ In vivo inhibition was measured by growth inhibition of strain lptD4213 ⌬dsbB dsbBPtrc[204] (CL409 –10, CL416 –7 and LI18 –19 strains) in the presence of drugs

Read more

Summary

Methods

Bacterial strains and growth conditionsThe strains and plasmids used in this study are listed in Tables 5 and 6, respectively. A mutagenic PCR of the dsbB gene using primers Cl13 and Cl14 was generated using the first seven mutagenic conditions of Diversify mutagenesis kit (Clontech) that on average generates 2–5.8 mutations/kb. 1 ␮l of the ligation reaction was transformed into highly competent XL1-Blue cells (Agilent Technologies). A sample of the colonies obtained after selection on ampicillin plates was collected for plasmid preparation used to confirm efficiency of ligation by PCR and digestion. Given that 9 of 10 colonies did have the expected insert, the rest of the ligation reaction (49 ␮l) was transformed into DH10␤ highly competent cells (New England Biolabs). The transformation yielded ϳ3,000 colonies, which were scraped up and grown overnight in M63 glucose for plasmid preparation.

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call